Skip to main content

Syndax Pharmaceuticals Inc

SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001395937

In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Syndax Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $784.8K in total
Insiders trading
1
Net value
−$784.8K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Syndax Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Syndax Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Metzger Michael AChief Executive Officer484,843Jul 9, 20264
Botwood Nicholas A.J.Head of R&D, CMO60,885Jun 12, 20262
Goldan Keith A.Chief Financial Officer139,252Jun 2, 20264
Podlesak DennisDirector239,763Feb 6, 20261
Katkin KeithDirector124,000Feb 6, 20261
Legault PierreDirector114,000Feb 6, 20261
Huber Martin H. Jr.Director103,000Feb 6, 20261
Jarrett JenniferDirector114,000Feb 6, 20261
Rizo AleksandraDirector49,000Feb 6, 20261
Gallagher NeilPresident, Head of R&D85,095Feb 12, 20250
Meury WilliamDirector90,000Feb 7, 20250
Morrison BriggsDirector34,836Feb 9, 20240
Ordentlich PeterChief Scientific Officer0Feb 17, 20230
Nolte AlexanderChief Accounting Officer0Feb 3, 20230
Madigan CatherineChief Medical Officer–Feb 3, 20230
Sabus Steve MChief Commercial Officer–Dec 5, 20220
Egros FabriceDirector32,000Feb 3, 20220
Meyers Michael L.SVP, Chief Medical Officer23,280Feb 3, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 9, 2026 (view filing)4:54 PM ETJul 81 dayMetzger Michael AChief Executive OfficerSSale−32.4K$24.24−$784.8K−6.3%484.8K after10b5-1
Jun 12, 2026 (view filing)Jun 11-121 dayBotwood Nicholas A.J.Head of R&D, CMOSSale−65.5K$18.07−$1.18M−51.8%60.9K after2 lots10b5-1
Jun 2, 2026 (view filing)Jun 11 dayGoldan Keith A.Chief Financial OfficerSSale−1.18K$18.99−$22.4K−0.8%139.3K after
Jun 2, 2026 (view filing)Jun 11 dayMetzger Michael AChief Executive OfficerSSale−6.85K$18.99−$130.0K−1.4%484.8K after
Feb 10, 2026 (view filing)Feb 91 dayMetzger Michael AChief Executive OfficerSSale−17.2K$21.03−$360.9K−3.4%491.7K after
Feb 10, 2026 (view filing)Feb 91 dayGoldan Keith A.Chief Financial OfficerSSale−3.41K$21.03−$71.7K−2.4%140.4K after
Feb 6, 2026 (view filing)Feb 6Same dayMetzger Michael AChief Executive OfficerSSale−7.41K$20.62−$152.8K−1.4%508.8K after
Feb 6, 2026 (view filing)Feb 6Same dayGoldan Keith A.Chief Financial OfficerSSale−2.08K$20.62−$42.9K−1.4%143.8K after
Sep 8, 2025 (view filing)Sep 8Same dayMetzger Michael AChief Executive OfficerSSale−157.3K$16.41−$2.58M−34.5%298.7K after10b5-1
Aug 18, 2025 (view filing)Aug 14-184 daysPodlesak DennisDirectorSSale−57.6K$15.19−$874.9K−23.1%191.8K after3 lots10b5-1
Jul 18, 2025 (view filing)Jul 162 daysGoldan Keith A.Chief Financial OfficerSSale−1.30K$9.29−$12.0K−1.4%92.5K after
Jul 18, 2025 (view filing)Jul 162 daysMetzger Michael AChief Executive OfficerSSale−7.53K$9.29−$70.0K−2.5%298.7K after
May 19, 2025 (view filing)May 19Same dayGoldan Keith A.Chief Financial OfficerPPurchase+3.00K––+3.3%93.7K after
May 19, 2025 (view filing)May 163 daysBotwood Nicholas A.J.Head of R&D, CMOPPurchase+11.8K$9.00+$105.9K+50.3%35.2K after
May 19, 2025 (view filing)May 19Same dayHuber Martin H. Jr.DirectorPPurchase+5.00K$8.99+$45.0K+6.8%79.0K after
May 19, 2025 (view filing)May 19Same dayKatkin KeithDirectorPPurchase+10.0K$9.11+$91.1K+11.1%100.0K after
Mar 6, 2025 (view filing)Mar 42 daysMetzger Michael AChief Executive OfficerSSale−7.81K$15.05−$117.6K−2.5%300.1K after10b5-1
Feb 12, 2025 (view filing)Feb 102 daysGoldan Keith A.Chief Financial OfficerSSale−3.78K$15.50−$58.5K−4.0%90.7K after
Feb 12, 2025 (view filing)Feb 102 daysMetzger Michael AChief Executive OfficerSSale−13.3K$15.50−$206.0K−4.2%300.1K after
Feb 12, 2025 (view filing)Feb 102 daysGallagher NeilPresident, Head of R&DSSale−4.62K$15.50−$71.6K−5.1%85.1K after
Jun 17, 2024 (view filing)Jun 143 daysGoldan Keith A.Chief Financial OfficerPPurchase+1.25K$20.03+$25.0K+2.4%52.6K after
Aug 10, 2023 (view filing)Aug 91 dayMorrison BriggsDirectorSSale−52.9K$18.27−$965.7K−74.8%17.8K after10b5-1
Aug 3, 2023 (view filing)Aug 21 dayMeury WilliamDirectorSSale−83.0K$20.46−$1.70M−63.4%48.0K after3 lots10b5-1
Jul 11, 2023 (view filing)Jul 101 dayMorrison BriggsDirectorSSale−52.9K$20.40−$1.08M−74.8%17.8K after10b5-1
Jun 14, 2023 (view filing)Jun 131 dayGoldan Keith A.Chief Financial OfficerSSale−577$22.31−$12.9K−18.0%2.63K after
Jun 9, 2023 (view filing)Jun 9Same dayMorrison BriggsDirectorSSale−52.9K$21.18−$1.12M−74.8%17.8K after2 lots10b5-1
May 10, 2023 (view filing)May 91 dayMorrison BriggsDirectorSSale−52.9K$21.41−$1.13M−74.8%17.8K after10b5-1
Apr 12, 2023 (view filing)Apr 102 daysMorrison BriggsDirectorSSale−52.9K$19.53−$1.03M−74.8%17.8K after10b5-1
Mar 14, 2023 (view filing)Mar 131 dayMorrison BriggsPresident, Head of R&DSSale−52.9K$22.53−$1.19M−74.8%17.8K after
Feb 17, 2023 (view filing)Feb 152 daysOrdentlich PeterChief Scientific OfficerSSale−25.0K$25.84−$646.0K−100.0%0 after2 lots
Feb 8, 2023 (view filing)Feb 62 daysMetzger Michael AChief Executive OfficerSSale−5.96K$27.64−$164.7K−25.2%17.7K after
Feb 8, 2023 (view filing)Feb 62 daysMorrison BriggsPresident, Head of R&DSSale−52.9K$26.83−$1.42M−74.8%17.8K after
Feb 3, 2023 (view filing)Feb 12 daysOrdentlich PeterChief Scientific OfficerSSale−69$28.43−$1.96K−100.0%0 after
Jan 13, 2023 (view filing)Jan 12-131 dayLegault PierreDirectorSSale−39.0K$26.84−$1.05M−54.9%32.0K after3 lots
Dec 2, 2022 (view filing)Dec 1-21 dayOrdentlich PeterChief Scientific OfficerSSale−25.0K$25.04−$625.9K−99.0%265 after3 lots
Oct 7, 2022 (view filing)Oct 61 dayKatkin KeithDirectorSSale−29.9K$25.90−$774.4K−48.3%32.0K after2 lots
Oct 7, 2022 (view filing)Oct 61 dayMetzger Michael AChief Executive OfficerSSale−16.2K$25.29−$410.5K−47.9%17.7K after
Oct 4, 2022 (view filing)Sep 30-Oct 44 daysMetzger Michael AChief Executive OfficerSSale−33.8K$25.02−$844.9K−65.7%17.7K after3 lots
Oct 4, 2022 (view filing)Sep 30-Oct 44 daysKatkin KeithDirectorSSale−4.10K$25.06−$102.8K−11.4%32.0K after6 lots
Sep 21, 2022 (view filing)Sep 19-202 daysMorrison BriggsPresident, Head of R&DSSale−174.0K$23.11−$4.02M−90.7%17.8K after2 lots
Sep 16, 2022 (view filing)Sep 14-162 daysMorrison BriggsPresident, Head of R&DSSale−279.4K$23.64−$6.60M−94.0%17.8K after4 lots
Sep 16, 2022 (view filing)Sep 15-161 dayPodlesak DennisDirectorSSale−78.8K$24.08−$1.90M−51.0%75.8K after3 lots
Aug 26, 2022 (view filing)Aug 242 daysOrdentlich PeterChief Scientific OfficerSSale−25.0K$25.04−$626.0K−99.0%265 after2 lots
Aug 9, 2022 (view filing)Aug 54 daysLegault PierreDirectorSSale−24.0K$23.02−$552.5K−42.9%32.0K after2 lots
Jul 27, 2022 (view filing)Jul 252 daysMetzger Michael AChief Executive OfficerSSale−31.6K$21.06−$665.5K−64.2%17.7K after2 lots
Jul 8, 2022 (view filing)Jul 6-72 daysMetzger Michael AChief Executive OfficerSSale−15.1K$21.07−$318.3K−46.1%17.7K after2 lots
Jul 5, 2022 (view filing)Jul 14 daysMorrison BriggsPresident, Head of R&DSSale−62.3K$19.00−$1.18M−77.7%17.8K after
Apr 5, 2022 (view filing)Apr 1-44 daysMorrison BriggsPresident, Head of R&DSSale−104.2K$17.48−$1.82M−85.4%17.8K afterAmended4 lots
Feb 3, 2022 (view filing)Feb 12 daysOrdentlich PeterChief Scientific OfficerSSale−1.41K$16.65−$23.5K−100.0%0 after
Feb 3, 2022 (view filing)Feb 12 daysNolte AlexanderChief Accounting OfficerSSale−968$16.65−$16.1K−100.0%0 after